Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

The Clinical Comparision of Amrinone and Dopamine after Open Heart Surgery

개심술후 암리논과 도파민의 효과에 대한 임상 비교

  • 이성호 (고려대학교 의과대학부속 안암병원 흉부외과) ;
  • 이현재 (고려대학교 의과대학부속 안암병원 흉부외과)
  • Published : 1996.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Amrinone is a non-glycosidic, non-adrenergic positive inotropic agent with peripheral and coronary vasodilator effect. It inhibits phosphodiesterase F-III, the cardiac cyclic-AMP specific phosphodiesterase, selectively and potently. In this study, the effects of IV administered amrinone and dopamine were compared in 40 patients who had open heart surgery. Amrinone was administered as a bolus of 1 5~2mglkg for several minutes, followed by continuous infusion at 5~1 Oug/kg/min. The hemodynamic measurements including heart rate, systolic and diastolic pressure, cardiac index, pulmonary wedge pressure, and systemic vascular resistance were recorded immediately for 12~24 hours awl 7th day following operation. In amrinone group, cardiac index increased from 3.73$\pm$1.39 L/min/m2 to 5.44$\pm$2.65 L/min/m2 at the time of posterative 48 hours (n=20, p< 0.05). The decrease in systemic vascular resistance from 1237.5 $\pm$ 637.7 dyne/sec/cm2 to 1000.8 $\pm$ 608.5 dyne/sec/cm2(p<0.05). In Dopamine group, the heart rate increased from 92.1 $\pm$ 13.0/min to 101.0 $\pm$ 13.1/min and the cardiac index decreased from 3.40 $\pm$ 0.50 L/min/m2 to 2.53 $\pm$ 1.15 L/min/m2 at the time of postoperative 12 hours(p<0.05). Systemic vascular resistance increased from 1058.5 $\pm$ 234.6 dyne/sec/cm2 to 1979.7 $\pm$ 759.2 dynelsec/cm2 The comparison of the hemodynamic effects of amrinone and dopamine, both drugs improved cardiac performance. But the administration of amrinone results in a higher cardiac index, diastolic blood pressure and lower systemic vascular resistance than those achieved with dopamine (p<0.05). The uniqueness of the action of amrinone on the heart and its sustained hemodynamic effect suggest it has clinical promise, pos operative care of cardiac surgery

암리논은 환식-AMP 분해 효소인 포스포다이에스트라제-F-III를 선택적으로 차단하는 비카테콜아민 계통의 약물로 심근세포내 환식-ATP의 양을 증가시켜 심근수축을 촉진한다. 이번 연구에서는 개심술을 시행한 40명의 환자에서 술후 암리논과도파민을 정맥주사하여 혈역학성 변화, 혈액성분변화, 합병증 들을 비교분석하였다. 혈역학성 변화로는 심박수, 수축기와 이완기 혈압, 심박출 계수, 폐동맥 쐐기압, 체혈관 저항 등을 수술직후부터 30분, 1시간, 3시간, 6시간, 12시간, 24시간, 48시간에 측정하였다. 암리논은 처음 초기 용량으로 1.5~2mg/kg을 주사한 후 유지량은 5~ 20ug/kg/min으로 주사하였다. 암리논에서 심박출계수는 수술직후 3.73$\pm$1.39 L/min/m2에서 술후 48시간에 5.44 $\pm$ 2.65 L/min/m2으로 증가하였고(p<0.05) 체혈관 저항은 1237.5 $\pm$ 637.7dyne/sec/cm2에서 1000.8 $\pm$ 608.5 dyne/sec/cm2으로 감소하였다. 도파민군에서 술후 12시 간에 심 박수가 92.1 $\pm$ 13.0/min에서 101.0 $\pm$ 13.1/min으로 증가하고 체혈관 저항도 1058.5 $\pm$ 234.6dyne/sec/cm2에서 1979.7 $\pm$ 759.2dyne/sec/cm2으로 증가하며 심 박출 계수는 3.40 $\pm$ 0.50L/min/m2에서 2 53 $\pm$ 1.15L/min/m2으로 감소하였다(p<0.05). 암리논을 사용한 군에서 도파민군과 비교하여 높은 심박출 계수와 낮은 체혈관 저항을 나타내어 혈역학성 동태에서 더 좋은 결과를 보였다. 술후 암리논의 사용이 좋은 혈역학성 동태를 유지하여 심근 보호 및 심장 기능회복에 좋을 것으로 생각한다.

Keywords

References

  1. Circulation v.59 Amrinone : A new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man LeJentel,T.H.;Keung,E.;Sonnenblick,E.(et al.)
  2. Chest v.94 Combination of high dose amrinone and dopamine in the management of cardiogenic shock after open heart surgery Oslen,K.H.;Kluger,J.;Fieldmann,A.
  3. N Engl J Med v.314 New positive inotropic agents in the treatment of congestive heart failure Colucci,W.S.;Wright,R.F.;Braunwald,E.
  4. Am J Physiol v.245 Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum Fabiato,A.
  5. Am Heart J v.107 c-AMP and phosphorylation in regulating of Ca++ influx into myocardial cell and blockade Ca antagonist drug Sperelaskis,N.
  6. Circ Res v.51 Stimulation of Ca++ binding and ATPase activity of dog cardiac myofibrils by AR-L 115BS, a novel cardiotonic agent (abstr) Solaro,R.J.;Ruegg,J.C.
  7. N Engl J Med v.291 Dopamine-clinical use of endogenous catecholamine Goldberg,L.I.
  8. Ann Thorac Surg v.52 Harmful effects of inotropic agents on myocardial protection Komai,H.;Yamamoto,F.;Tanaka,K.
  9. Fed Proc v.37 Cardiotonic activity of amrinone (WIN 40680) Aloasi,A.;Farah,A.E.;Lesher,G.Y.(et al.)
  10. Textbook of medical physiology(8th ed.) Contraction and excitation of smooth muscle Guyton,A.C.
  11. Cardiovasc Res v.14 Effects of amrinone on experimental acute myocardial ischemia injury (abstr) Rude,R.E.;Kloner,K.A.;Macoko,P.R.(et al.)
  12. Circulation v.60 no.SUP.Ⅱ The beneficial effects of amrinone on myocardial oxygen consumption during acute left ventricular failure Jentzer,J.H.;LeJemtel,T.H.;Kirk,E.S.(et al.)
  13. Am J Cardiol v.64 no.18 Comparision of Doppler indices of LV diastolic function with simultaneous high left atrial and ventricular pressure in idiopathic dilated cardiomyopathy David,D.;Lang,R.H.;Neumann,A.(et al.)
  14. Prog-Cardiovasc Nurse v.5 no.3 Management of heart failure in cardiac surgical patients : Amrinone and other pharmacological agents LeDoux,D.
  15. Acta Anaesthesiol Scand v.34 no.6 Amrinone in perioperative low cardiac output syndrome Fita,G.;Gormar,C.;Jimenez,M.J.(et al.)
  16. Euro J Anaesthesiol no.SUP.5 Perioperative experience with Amrinone (reniew) Levy,G.;Bailey,J.M.
  17. Am J Med v.72 Relative contribution of inotropic and vasodilator effects to amrinone induced hemodynamic improvement in congestive heart failure Konstam,M.A.;Cohen,S.R.;Weiland,D.S.(et al.)
  18. Chest v.99 Effect of amrinone on cardiac index, venous oxygen saturation and venous admixture in patients recovering from cardiac surgery Prielipp,R.C.;Butterworth,J.F.;Zaloga,G.P.(et al.)
  19. Am J Med v.56 Clinical safety of intravenous amrinone-review Treadyway,G.
  20. AHFS Drug information Amrinone lactate Mcevoy,G.K.
  21. South-Med J v.82 no.10 Pulmonary embolism : improvement in hemodynamic function with amrinone therapy (abstr) Spencer,T.H.;Newton,W.D.